[1] Hue S, Beldi-Ferchiou A, Bendib I, et al. Uncontrolled innate and impaired adaptive immune responses in patients with COVID-19 acute respiratory distress syndrome [J]. Am J Respir Crit Care Med, 2020, 202(11): 1509-1519. DOI: 10.1164/rccm.202005-1885OC.
[2] Ghembaza A, Vautier M, Cacoub P, et al. Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases [J]. Chest, 2020, 158(6): 2323-2332. DOI: 10.1016/j.chest.2020.05.558.
[3] Wang Y, Pang SC, Yang Y. A potential association between immunosenescence and high COVID-19 related mortality among elderly patients with cardiovascular diseases [J]. Immun Ageing, 2021, 18(1): 25. DOI: 10.1186/s12979-021-00234-z.
[4] Bienvenu AL, Traore K, Plekhanova I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients [J]. Int J Infect Dis, 2016, 46: 11-17. DOI: 10.1016/j.ijid.2016.03.018.
[5] Nasr M, Mohammad A, Hor M, et al. Exploring the differences in pneumocystis pneumonia infection between HIV and non-HIV patients [J]. Cureus, 2022, 14(8): e27727. DOI:10.7759/cureus.27727.
[6] 代艳, 李新叶, 唐慧荷, 等. 非HIV感染的免疫低下者肺孢子菌肺炎防治进展[J]. 中国临床新医学, 2021, 14(2): 134-138. DOI: 10.3969/j.issn.1674-3806.2021.02.04.
[7] Asai N, Motojima S, Ohkuni Y, et al. Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection [J]. J Infect Chemother, 2012, 18(6): 898-905. DOI: 10.1007/s10156-012-0441-4.
[8] Chong WH, Saha BK, Austin A, et al. The significance of subpleural sparing in CT chest: a state-of-the-art review [J]. Am J Med Sci, 2021, 361(4): 427-435. DOI: 10.1016/j.amjms.2021.01.008.
[9] 张为,佘丹阳,谢晓玮,等. 二代测序技术在非人类免疫缺陷病毒感染者肺孢子菌肺炎诊断中的应用价值[J]. 中华结核和呼吸杂志,2020,43(10):844-849. DOI: 10.3760/cma.j.cn112147-20200416-00510.
[10] Tasaka S. Recent advances in the diagnosis and management of pneumocystis pneumonia [J]. Tuberc Respir Dis (Seoul), 2020, 83(2): 132-140. DOI:10.4046/trd.2020.0015.
[11] Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment [J]. Expert Opin Pharmacother, 2021, 22(12): 1579-1592. DOI:10.1080/14656566.2021.1915989.
[12] 段艳,徐媛,雷雯朴,等. 非HIV人群感染耶氏肺孢子菌肺炎的诊治研究进展[J]. 中国真菌学杂志,2022,17(5):435-440. DOI:10.3969/j.issn.1673-3827.2022.05.020.
[13] Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii pneumonia [J]. Infect Dis Clin North Am, 2010, 24(1): 107-138. DOI: 10.1016/j.idc.2009.10.010.
[14] Povoa P, Coelho L, Salluh J. When should we use corticosteroids in severe community-acquired pneumonia? [J]. Curr Opin Infect Dis, 2021, 34(2): 169-174. DOI:10.1097/QCO.0000000000000709.
[15] Wang M, Zhang Z, Dong X, et al. Targeting beta-glucans, vital components of the pneumocystis cell wall [J]. Front Immunol, 2023, 14: 1094464. DOI: 10.3389/fimmu.2023.1094464.
|